

Amendments to the Claims

[[1-]] 1. (Currently Amended) A pharmaceutical combination for the treatment of neoplasia through simultaneous, separate, or sequential administration, comprising a compound A and B, wherein A is selected from the group of molecules consisting of:

- [[1.]] a) GnRH, or its analogues, or anti-GnRH antibodies, or GnRH receptor (GnRH-R), or its mutated variants, or derivative peptides, or anti-GnRH-R antibodies, coupled or not to an immunopotentiating carrier protein;
- [[2.]] b) natural or recombinant gonadotropins, or their analogues, or their mutated variants, coupled or not to an immunopotentiating carrier protein, hypophyseal anti-gonadotropin antibody, their Fabs, scFV fragments, humanized or not;
- [[3.]] c) hypophyseal gonadotropin receptors, or their mutated variants, or derivative peptides, coupled or not to an immunopotentiating carrier protein; and
- [[4.]] d) hypophyseal gonadotropin anti-receptor antibodies, their Fabs, scFV fragments, humanized or not;

and wherein B is selected from the group of molecules consisting of:

- [[1.]] a) natural or recombinant EGF or its mutated variants, or derivative peptides, or EGF mimetic peptides, or EGF analogues, coupled or not to an immunopotentiating carrier protein;
- [[2.]] b) anti-EGF antibodies, their FabsscFV fragments, humanized or not;
- [[3.]] c) EGF receptor (EGF-R), or its mutated variants, or derivative peptides coupled or not to an immunopotentiating carrier protein;
- [[4.]] d) anti-EGF receptor antibodies, their Fabs, scFV fragments, humanized or not;
- [[5.]] e) natural or recombinant VEGF or mutated variants, or derivative peptides, or VEGF mimetic peptides, or VEGF analogues, coupled or not to an immunopotentiating carrier protein;
- [[6.]] f) anti-VEGF antibodies, their Fabs, scFV fragments, humanized or not;

Applicants: Bover Fuentes et al.

Serial No.: 10/539,172

Filed: March 29, 2006

Preliminary Amendment filed September 24, 2009

Page 3 of 5

[[7.]] g) VEGF receptors, or mutated variants, or derivative peptides from VEGF receptors,

coupled or not to an immunopotentiating carrier protein;

[[8.]] h) anti-VEGF receptor antibodies, their Fabs, scFV fragments, humanized or not;

[[9.]] i) natural or recombinant TGF or mutated variants, or derivative peptides, or TGF mimetic peptides, or TGF analogues, coupled or not to an immunopotentiating carrier protein;

[[10.]] j) anti-TGF antibodies, their Fabs, scFV fragments, humanized or not; and

[[11]] k) TGF receptor (TGF-R), or mutated variants, or derivative peptides coupled or not to an immunopotentiating carrier protein.

[[2-]] 2 (Currently Amended) A combination according to claim 1, wherein the A and B group of molecules are coupled to the immunopotentiating carrier protein by conjugation or the formation of chimeric proteins.

[[3-]] 3 (Currently Amended) A combination according to claim 1, wherein the GnRH analogue peptide has sequence pGlu-His-Trp-Ser-Tyr-Pro-Leu-Arg-Pro-Gly (SEQ ID NO: 1), coupled to an immunopotentiating carrier protein.

[[4-]] 4 (Currently Amended) A combination according to claim 1, wherein the immunopotentiating carrier protein is selected from *Neisseria meningitidis* P1 and P64 outer membrane proteins.

[[5-]] 5 (Currently Amended) A combination according to claim 1, wherein the immunopotentiating carrier protein is a Tetanic Toxoid (TT) T helper epitope.

[[6-]] 6 (Currently Amended) A combination according to claim 1, wherein the conjugated chimeric protein is one of the following variants:

Applicants: Bover Fuentes et al.

Serial No.: 10/539,172

Filed: March 29, 2006

Preliminary Amendment filed September 24, 2009

Page 4 of 5

- a) GnRH bound to a carrier protein and to EGF;
- b) GnRH bound to a carrier protein and to VEGF;
- c) GnRH bound to a carrier protein and to TGF;
- d) GnRH bound to a carrier protein, to EGF and TGF; or
- e) GnRH bound to a carrier protein, to VEGF and EGF.

[[7-]] 7. (Withdrawn- currently amended) A method for the generation of combined immune response comprising treatment with the therapeutic combination according to claim 1.

[[8-]] 8. (Withdrawn- currently amended) A method according to claim 7, wherein the combination can be applied simultaneously, separately, or sequentially.